Completed PHASE2 INTERVENTIONAL 1-arm NCT00959686

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma (BENTLY)

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma. A Phase II Multicenter Study BENTLY

Sponsor: French Innovative Leukemia Organisation

Updated 5 times since 2017 Last updated: Feb 11, 2013 Started: Sep 30, 2009 Primary completion: Jun 30, 2011 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on T-cell Lymphoma, this trial is completed. The trial is conducted by French Innovative Leukemia Organisation and has accumulated 5 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

French Innovative Leukemia Organisation
Mundipharma Pte Ltd.

Data source: French Innovative Leukemia Organisation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amiens, France